-
Product Insights
New![]()
Net Present Value Model: PDS Biotechnology Corp’s PDS-0101
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Alkyon PD/ ICAG – Romanowicza Student Accommodation – Lesser Poland Voivodeship
Equip yourself with the essential tools needed to make informed and profitable decisions with our Alkyon PD/ ICAG – Romanowicza Student Accommodation – Lesser Poland Voivodeship report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Acquire a thorough understanding...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PD-0360324 in Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PD-0360324 in Ovarian Cancer Drug Details: PD-360324 is under development for treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PD-0360324 in Gastric Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PD-0360324 in Gastric Cancer Drug Details: PD-360324 is under development for treatment of solid tumors...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0101 in Oropharyngeal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PDS-0101 in Oropharyngeal Cancer Drug Details: PDS-0101 is under development for the treatment of HPV-induced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0101 in Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. PDS-0101 in Lung Cancer Drug Details: PDS-0101 is under development for the treatment of HPV-induced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Oropharyngeal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Oropharyngeal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0101 in Esophageal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0101 in Esophageal Cancer Drug Details:PDS-0101 is under development for the treatment of HPV-induced cancers which...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Kaposi Sarcoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Kaposi Sarcoma Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – PDS-0301 in Vaginal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.PDS-0301 in Vaginal Cancer Drug Details:PDS-0301 (M-9241, MSB-0010360) (NHS-Interleukin-12) is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.